Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

OMER PEER ANALYSIS

Omeros Corporation — metric-by-metric comparison with peers and the industry median

OMEROmeros Corporation

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Biotechnology

Return Comparison

1-Year
Split-adjusted
OMER+223.1%MSB+27.6%TLX-28.2%RTALB+24.1%CSL-47.6%
Year-to-Date (YTD)
OMER-39.8%MSB-23.5%TLX+55.2%RTALB+5.0%CSL-27.1%
1-Year
Split-adjusted
OMER+223.1%MDXG-35.8%ZURA+374.3%DNA-20.5%ARVN+6.3%PRTA+47.6%
Year-to-Date (YTD)
OMER-39.8%MDXG-39.9%ZURA+2.3%DNA+21.7%ARVN-28.8%PRTA-0.5%

Key Metric Comparison

P/E

Lower is better
OMER—MSB—TLX—RTALB4.89CSL30.02Median 17.81

ROE

Higher is better
OMER—MSB-11.3%TLX-1.8%RTALB15.1%CSL7.7%Median -47.5%

Net Margin

Higher is better
OMER—MSB-115.3%TLX-0.9%RTALB136.3%CSL9.2%Median -125.7%

Revenue Growth

Higher is better
OMER—MSB410.4%TLX56.3%RTALB24.0%CSL4.8%Median 5.1%

P/E

Lower is better
OMER—MDXG19.68ZURA—DNA—ARVN—PRTA—Median 17.81

ROE

Higher is better
OMER—MDXG13.8%ZURA-42.5%DNA-55.8%ARVN-42.3%PRTA-40.3%Median -47.5%

Net Margin

Higher is better
OMER—MDXG7.9%ZURA—DNA-215.4%ARVN-247.5%PRTA-260.9%Median -125.7%

Revenue Growth

Higher is better
OMER—MDXG10.5%ZURA-100.0%DNA-40.5%ARVN-79.1%PRTA-58.0%Median 5.1%

All Metrics

Valuation
MetricOMERMSBTLXRTALBCSLInd. Median
P/E———4.89●30.0217.81
P/B-10.37●—6.560.612.243.49
EV/EBITDA——123.3174.6110.37●14.92
P/S—31.913.346.672.67●10.89
Financial Health
MetricOMERMSBTLXRTALBCSLInd. Median
Current Ratio3.03●—1.431.212.575.90
Debt/Equity-490.5%●—112.3%1.2%67.4%10.9%
NetDebt/EBITDA——13.130.90●2.221.15
Profitability
MetricOMERMSBTLXRTALBCSLInd. Median
Net Margin—-115.3%-0.9%136.3%●9.2%-125.7%
ROE—-11.3%-1.8%15.1%●7.7%-47.5%
ROA—-8.6%-0.7%13.1%●3.8%-35.8%
EBITDA Margin—-76.6%3.0%9.0%32.8%●-105.8%
Growth + Dividend
MetricOMERMSBTLXRTALBCSLInd. Median
Rev. Growth—410.4%●56.3%24.0%4.8%5.1%
NI Growth———134.0%●-39.4%12.1%
Div. Yield—0.0%—0.0%2.5%●0.2%
Payout—0.0%—0.0%103.1%0.0%
Valuation
MetricOMERMDXGZURADNAARVNPRTAInd. Median
P/E—19.68————17.81
P/B-10.37●2.492.771.361.401.643.49
EV/EBITDA—8.07————14.92
P/S—1.55●—4.266.058.8710.89
Financial Health
MetricOMERMDXGZURADNAARVNPRTAInd. Median
Current Ratio3.035.3919.33●5.155.4410.435.90
Debt/Equity-490.5%●7.2%—92.7%2.2%2.4%10.9%
NetDebt/EBITDA—-2.48●—-0.182.804.311.15
Profitability
MetricOMERMDXGZURADNAARVNPRTAInd. Median
Net Margin—7.9%●—-215.4%-247.5%-260.9%-125.7%
ROE—13.8%●-42.5%-55.8%-42.3%-40.3%-47.5%
ROA—10.6%●-37.6%-26.2%-26.8%-35.8%-35.8%
EBITDA Margin—14.7%●—-149.2%-242.2%-129.0%-105.8%
Growth + Dividend
MetricOMERMDXGZURADNAARVNPRTAInd. Median
Rev. Growth—10.5%●-100.0%-40.5%-79.1%-58.0%5.1%
NI Growth—-23.6%————12.1%
Div. Yield——————0.2%
Payout——————0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on OMER

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.